Aurobindo gets USFDA nod for anti-HIV drug
Aurobindo Pharma Ltd on Wednesday said it has received tentative approval by USFDA for its anti-HIV drug, Didanosine chewable tablets of 100mg, 150mg and 200mg strengths.
By PTI |
MUMBAI: Aurobindo Pharma Ltd on Wednesday said it has received tentative approval by USFDA for its anti-HIV drug, Didanosine chewable tablets of 100mg, 150mg and 200mg strengths.
This is the first generic version approval for Didanosine chewable in the world given by USFDA, Aurobindo Pharma informed the Bombay Stock Exchange.
The aforesaid product would now be available for purchase under the President's Emergency Plan for AIDS Relief (PEPFAR), it added.
The company manufactures both Active Pharmaceutical Ingredients (API) and formulation for this generic version and with this approval, the antiretroviral (ARV) product portfolio of the company increased to 17.
Didanosine is a Nucleoside reverse transcriptase inhibitor (NRTI) class of drugs, and a key component of the ARV regimens in various parts of the world.
ADVERTISEMENT
The drug helps prevent AIDS virus from reproducing. It is used in combination with other antiretroviral agents for the treatment of HIV-1 infection. It is the version of VIDEX an anti-HIV medication manufactured by Bristol Myers Squibb.The shares of the company were trading at Rs 608, up 2.16 per cent at the BSE.
Start a SIP with as low as ₹500 with ET Money App!
Download
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
ADVERTISEMENT
